Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Potere Health MD vs RxSpan MD

By GLP-1 ScorecardUpdated

Potere Health MDFactor scores not reassessed.
Site position #87

Lower score

RxSpan MD
Site position #4

Higher score

Score comparison

RxSpan MD has the higher recorded score — 84.3/100 to 72.5/100.

RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.

Before you choose

RxSpan MD does not publish a semaglutide price, so its RxSpan MD review sets out what it does disclose, while the Potere Health MD review explains the conditions attached to Potere Health MD's figure. The semaglutide cost page compares published rates across the field. Ask RxSpan MD for a written total before treating either one as the cheaper choice.

If neither one fits, Potere Health MD vs Sunlight.com and Push Health vs RxSpan MD compare each of them with another graded program, and the list of alternatives to Potere Health MD ranks the programs closest to Potere Health MD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueRxSpan MD +1
85
86
Dose & formulationRxSpan MD +25
64
89
Clinical oversightRxSpan MD +1
87
88
Labs & monitoringRxSpan MD +29
54
83
FulfillmentRxSpan MD +22
67
89
Contract termsPotere Health MD +8
61
53
Potere Health MD · top barRxSpan MD · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricPotere Health MDRxSpan MD
WeighScore72.5/10084.3/100
GradeCB
Site position#87#4
Semaglutide$239 upfront for the advertised 10 mg compounded vial; usable supply variesCurrent compounded quote unconfirmed
Tirzepatide$119 for the advertised four-week compounded starting order or $350 upfront for the larger vialCurrent compounded quote unconfirmed
Coverage1 stateConfirm treatment availability during intake
Brand-name accessYesYes
Oral / sublingualNot confirmedNot confirmed
Potere Health MD

Site position #87 · C

Factor scores not reassessed.

Strengths

  • Posts upfront purchase amounts for compounded options
  • Advertises Utah telehealth and in-person appointments
  • Discusses branded options separately

What to consider

  • Monthly estimates are not the amount due at purchase
  • Usable supply depends on the prescription and pharmacy label
  • Ask which charges and refund rules apply to the selected order
RxSpan MD

Site position #4 · B

Strengths

  • Current public catalog lists Ozempic, Wegovy, Mounjaro and Zepbound
  • Public terms describe independent healthcare providers
  • Homepage describes messaging and care-team appointments

What to consider

  • Homepage advertises compounded plans that the current catalog did not substantiate
  • Current oral GLP-1 availability is unconfirmed
  • Prior compounded prices are not a current quote; selected dose, supply, pharmacy and fee inclusions need confirmation
  • Public terms do not establish unused prepaid-treatment refund amounts

Featured provider

RxSpan MD

RxSpan MD scores 84.3/100 (B). RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard